OLDWICK, N.J., Sept. 25, 2019 /PRNewswire/ -- Provention Bio,
Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company
dedicated to intercepting and preventing immune-mediated diseases,
today announced that management will present at the 2019 Cantor
Global Healthcare Conference on Wednesday, October 2, 2019,
at 4:45 pm E.T. The conference is being held at the
InterContinental New York Barclay Hotel, New York,
NY.
The presentation will be webcast live and can be accessed by
visiting the Events and Webcasts section of the Company's
website: http://investors.proventionbio.com/events. A replay
of the webcast will be archived on the Company's website for 90
days following the presentation.
About Provention Bio, Inc.
Provention Bio, Inc. (Nasdaq: PRVB) is a clinical-stage
biopharmaceutical company leveraging a transformational drug
development strategy that is focused on the prevention or
interception of immune-mediated disease. Provention's mission is to
in-license, transform and develop therapeutic candidates targeting
the high morbidity, mortality and escalating costs of autoimmune
and inflammatory diseases including: type 1 diabetes (T1D), Crohn's
disease, celiac disease and lupus. Provention's diversified
portfolio includes advanced-stage product development candidates
that have undergone clinical testing by other companies.
Investors:
Sam Martin,
Argot Partners
sam@argotpartners.com
212-600-1902
Media:
David Rosen
david.rosen@argotpartners.com
212-600-1902
View original content to download
multimedia:http://www.prnewswire.com/news-releases/provention-bio-to-present-at-the-2019-cantor-global-healthcare-conference-300924759.html
SOURCE Provention Bio, Inc.